Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is approved
for clinical use in the treatment of non-small cell lung cancer (NSCLC). According to …

Gefitinib, an EGFR receptor tyrosine kinase inhibitor, is approved for clinical use in the
treatment of non-small cell lung cancer (NSCLC), but the emergence of mutations resistant …

BACKGROUND: Several studies implicated that lung cancer progression was governed by
the interaction between estrogen receptor (ER) and epidermal growth factor receptor …

Introduction. Epidermal growth factor receptor (EGFR) mutations are known as oncogene
driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine …

Lung cancer (LC) is the leading cause of cancer death in men worldwide and has
significantly increased in women. Differences in non-small cell lung cancer (NSCLC) …

Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …

Identifying new effective therapeutic treatments for lung cancer is critical to improving overall
patient survival. We have targeted both the estrogen receptor (ER) and the epidermal growth …

Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth
factor receptor (EGFR), which had antitumor activity in patients with previously treated non …

Background: The aim of the present study was to determine the prognostic significance of
the combined overexpression of epidermal growth factor receptor (EGFR) and estrogen …

There is growing evidence that estrogen receptors (ER) are expressed in lung cancer cells,
and are able to interact with the epidermal growth factor receptor (EGFR) signaling pathway …